Physician profile
Suzan Buxton
NPI 1386861235
$2,473.86
in general payments reported to CMS, 2019-2025
25 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $152 · 2021: $362 · 2022: $436 · 2023: $510 · 2024: $491 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $43.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.31 |
| Education | $43.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $361.85 | 2019-2024 | Farxiga, Lokelma |
| Novo Nordisk INC | $260.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Akebia Therapeutics INC | $244.23 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $232.99 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $193.51 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $172.19 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $153.68 | 2023-2024 | |
| Amgen INC. | $125.86 | 2024-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $88.00 | 2021-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $79.70 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $74.96 | 2021-2024 | Acthar |
| Ultragenyx Pharmaceutical INC. | $64.35 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.85 | 2023-2024 | Injectafer |
| Glaxosmithkline, LLC. | $51.27 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $42.41 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.28 | 2022-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $39.08 | 2022-2024 | |
| Lilly USA, LLC | $38.04 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $33.83 | 2024 | |
| Ani Pharmaceuticals, INC. | $22.74 | 2022 | |
| Ardelyx, INC. | $22.37 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.81 | 2024 | Jardiance |
| Boston Scientific Corporation | $19.78 | 2023 | |
| Renalytix Ai, INC. | $16.92 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Arbor Pharmaceuticals, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan Buxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.